A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

Inclusion Criteria:

• Weight ≥ 50 kilograms (kg), at screening and first admission, and body mass indexbetween 18.0 kilogram per square meter (kg/m^2) and 32.0 kg/m^2, inclusive, atscreening.

• A negative QuantiFERON-TB Gold test result at screening or documentation of anegative result within 3 months before screening.

• Normal renal function at screening as evidenced by an estimated glomerularfiltration rate (eGFR) ≥ 80 milliliter per minute (mL/min)/1.732 m^2 calculated withthe Chronic Kidney Disease Epidemiology Collaboration formula.

Exclusion Criteria:

• Any significant acute or chronic medical illness.

• Current or recent (within 3 months of study drug administration) gastrointestinal (GI) disease that could impact upon the absorption of study treatment.

• GI surgery, including cholecystectomy, that could impact upon the absorption ofstudy treatment, at the investigator's discretion.